Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 4Hematologic Neoplasms 3Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Waldenstrom Macroglobulinemia 1Recurrence 1Plasmacytoma 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

fludarabine phosphate 52Cyclophosphamide 52Peripheral Blood Stem Cell Transplantation 50Rituximab 47Mycophenolic Acid 34Whole-Body Irradiation 33Tacrolimus 26Cyclosporine 25Busulfan 23Etoposide 21Filgrastim 19Methotrexate 18Melphalan 18Antilymphocyte Serum 18Radiotherapy 15Bortezomib 15Sirolimus 12Lenalidomide 11ibrutinib 9Flow Cytometry 9Cyclosporins 9Everolimus 8Dexamethasone 8Carboplatin 8sargramostim 7Polymerase Chain Reaction 7Methylprednisolone 7Indium 7Cytarabine 7idelalisib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × ixazomib × Other hematologic neoplasm × Clear all
NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Active not recruiting
33 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡